Laboratory Corporation of America Holdings

NYSE LH

Laboratory Corporation of America Holdings EBIT Margin for the Trailing 12 Months (TTM) ending December 31, 2024: 8.51%

Laboratory Corporation of America Holdings EBIT Margin is 8.51% for the Trailing 12 Months (TTM) ending December 31, 2024, a 41.83% change year over year. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.

Laboratory Corporation of America Holdings EBIT Margin for the Trailing 12 Months (TTM) ending December 31, 2023 was 6.00%, a -49.37% change year over year.
Laboratory Corporation of America Holdings EBIT Margin for the Trailing 12 Months (TTM) ending December 31, 2022 was 11.85%, a -42.78% change year over year.
Laboratory Corporation of America Holdings EBIT Margin for the Trailing 12 Months (TTM) ending December 31, 2021 was 20.71%, a 14.95% change year over year.
Laboratory Corporation of America Holdings EBIT Margin for the Trailing 12 Months (TTM) ending December 31, 2020 was 18.02%, a 55.73% change year over year.

Key data

Date	EBIT Margin	EPS (Basic)	EPS (Diluted)	Shares (Basic, Weighted)

NYSE: LH

Laboratory Corporation of America Holdings

CEO	Mr. Adam H. Schechter
IPO Date	March 29, 1990
Location	United States
Headquarters	358 South Main Street
Employees	67,000
Sector	Healthcare
Industries Biotechnology Clinical Trials Drugstores & Retail Pharmacies Medical Instruments Personal Care Pharmaceuticals Telehealth Vaccines

Description

Laboratory Corporation of America Holdings operates as a global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, and parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. It provides online and mobile applications to enable patients to check test results; and online applications for managed care organizations and accountable care organizations. It offers end-to-end drug development, medical device, and companion diagnostic development solutions from early-stage research to clinical development and commercial market access. It serves managed care organizations, pharmaceutical, biotechnology, medical device and diagnostics companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, and independent clinical laboratories. Laboratory Corporation of America Holdings has a collaboration agreement with Tigerlily Foundation to increase clinical trial diversity for women of color. The company was incorporated in 1994 and is headquartered in Burlington, North Carolina.

Key trends

Past 5 years